Orchard Therapeutics (ORTX) News and press releases

Orchard Therapeutics Inc (NASDAQ: ORTX) announced multiple clinical and preclinical updates from its portfolio of investigational hematopoietic stem cell (HSC) gene therapies in neurometabolic

New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates, improvement in joint function and progressive acquisition of

Orchard Therapeutics (NASDAQ:ORTX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(1.66) by 92.77 percent. This is a 65.71 percent increase over losses of $(0.35) per share

B of A Securities cut the price target for Fox Corporation (NASDAQ: FOXA) from $42 to $34. B of A Securities analyst Jessica Reif Ehrlich downgraded the stock from Buy to Neutral. Fox shares fell 1.8% to $33.03 in pre-market trading.

Cantor Fitzgerald analyst Pete Stavropoulos maintains Orchard Therapeutics (NASDAQ:ORTX) with a Overweight and raises the price target from $3 to $15.

Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb.

Orchard Therapeutics (NASDAQ:ORTX) reported quarterly losses of $(0.06) per share. This is a 79.31 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has entered into a securities purchase agreement for the sale of ordinary shares and warrants in a private placement that could bring in up to $188 million at increasing valuations following the achievement of U.S.

New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates, improvement in joint function and progressive acquisition of

Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn's disease, a severe and treatment-refractory form of the disease In vivo data demonstrate the development of CAR-Treg cells from

PRESS RELEASE OMass Therapeutics Announces Appointment of New Board Chairand Series B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and

Six presentations showcase the differentiated profile and broad applicability of the company's HSC gene therapy platform Oral presentations in MPS-IH and MPS-IIIA and the progranulin form of frontotemporal dementia

BOSTON and LONDON, March 30, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at the Guggenheim Genomic

BOSTON and LONDON, March 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the Company's previously disclosed change to its American Depositary Share

OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA) Strategic financing from leading healthcare investors provides up

Proceeds to accelerate commercialization of Libmeldy and advance the company's HSC gene therapy R&D portfolio Initial closing of $34 million to support execution and extend cash runway into 2025 with potential for

BOSTON and LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that members of the management team will present at the following investor